Liver Fibrosis-Pipeline Review, H1 2017

Liver Fibrosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9179IDB
  • |
  • Pages: 200
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Liver Fibrosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis-Pipeline Review, H1 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape.

Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Fibrosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 1, 46 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 8 molecules, respectively.

Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Liver Fibrosis-Overview 6

Liver Fibrosis-Therapeutics Development 7

Liver Fibrosis-Therapeutics Assessment 18

Liver Fibrosis-Companies Involved in Therapeutics Development 30

Liver Fibrosis-Drug Profiles 53

Liver Fibrosis-Dormant Projects 177

Liver Fibrosis-Discontinued Products 180

Liver Fibrosis-Product Development Milestones 181

Appendix 191

List of Figures

Number of Products under Development for Liver Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Liver Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Liver Fibrosis-Pipeline by AdAlta Ltd, H1 2017

Liver Fibrosis-Pipeline by Advinus Therapeutics Ltd, H1 2017

Liver Fibrosis-Pipeline by Allergan Plc, H1 2017

Liver Fibrosis-Pipeline by Angion Biomedica Corp, H1 2017

Liver Fibrosis-Pipeline by Asubio Pharma Co Ltd, H1 2017

Liver Fibrosis-Pipeline by aTyr Pharma Inc, H1 2017

Liver Fibrosis-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017

Liver Fibrosis-Pipeline by BioLineRx Ltd, H1 2017

Liver Fibrosis-Pipeline by Bioneer Corp, H1 2017

Liver Fibrosis-Pipeline by BiOrion Technologies BV, H1 2017

Liver Fibrosis-Pipeline by Bird Rock Bio Inc, H1 2017

Liver Fibrosis-Pipeline by Cellmid Ltd, H1 2017

Liver Fibrosis-Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Pipeline by Dr. Falk Pharma GmbH, H1 2017

Liver Fibrosis-Pipeline by Dynavax Technologies Corp, H1 2017

Liver Fibrosis-Pipeline by Evotec AG, H1 2017

Liver Fibrosis-Pipeline by Galectin Therapeutics Inc, H1 2017

Liver Fibrosis-Pipeline by Genfit SA, H1 2017

Liver Fibrosis-Pipeline by GenKyoTex SA, H1 2017

Liver Fibrosis-Pipeline by GNI Group Ltd, H1 2017

Liver Fibrosis-Pipeline by HanAll Biopharma Co Ltd, H1 2017

Liver Fibrosis-Pipeline by HEC Pharm Co Ltd, H1 2017

Liver Fibrosis-Pipeline by Immuron Ltd, H1 2017

Liver Fibrosis-Pipeline by Intercept Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Pipeline by Isarna Therapeutics GmbH, H1 2017

Liver Fibrosis-Pipeline by KineMed Inc, H1 2017

Liver Fibrosis-Pipeline by Nitto Denko Corp, H1 2017

Liver Fibrosis-Pipeline by Pfizer Inc, H1 2017

Liver Fibrosis-Pipeline by Pharmaxis Ltd, H1 2017

Liver Fibrosis-Pipeline by Promedior Inc, H1 2017

Liver Fibrosis-Pipeline by Promethera Biosciences SA, H1 2017

Liver Fibrosis-Pipeline by ProMetic Life Sciences Inc, H1 2017

Liver Fibrosis-Pipeline by Ribomic Inc, H1 2017

Liver Fibrosis-Pipeline by RXi Pharmaceuticals Corp, H1 2017

Liver Fibrosis-Pipeline by Samumed LLC, H1 2017

Liver Fibrosis-Pipeline by Silence Therapeutics Plc, H1 2017

Liver Fibrosis-Pipeline by Sirnaomics Inc, H1 2017

Liver Fibrosis-Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Liver Fibrosis-Pipeline by TCM Biotech International Corp, H1 2017

Liver Fibrosis-Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Pipeline by Vascular Biogenics Ltd, H1 2017

Liver Fibrosis-Pipeline by Virobay Inc, H1 2017

Liver Fibrosis-Pipeline by XTuit Pharmaceuticals Inc, H1 2017

Liver Fibrosis-Dormant Projects, H1 2017

Liver Fibrosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Liver Fibrosis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Liver Fibrosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc, XTuit Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com